UBS Group
GANX icon

UBS Group’s Gain Therapeutics GANX Stock Holding History

UBS Group’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$436K Sell
215,012
-5,477
-2% -$10.1K ﹤0.01% 6330
2026
Q1 		$428K Buy
220,489
+139,368
+172% +$303K ﹤0.01% 6188
2025
Q4 		$261K Sell
81,121
-59,556
-42% -$159K ﹤0.01% 6436
2025
Q3 		$249K Buy
140,677
+108,042
+331% +$182K ﹤0.01% 6542
2025
Q2 		$58.7K Sell
32,635
-10,725
-25% -$19.8K ﹤0.01% 7640
2025
Q1 		$82.8K Buy
43,360
+8,133
+23% +$18K ﹤0.01% 7193
2024
Q4 		$76.1K Buy
35,227
+26,772
+317% +$53.7K ﹤0.01% 7042
2024
Q3 		$15.1K Sell
8,455
-2,967
-26% -$3.73K ﹤0.01% 7525
2024
Q2 		$14.6K Buy
11,422
+2,749
+32% +$7.14K ﹤0.01% 7503
2024
Q1 		$32.7K Sell
8,673
-5,350
-38% -$22.2K ﹤0.01% 6695
2023
Q4 		$45.8K Buy
14,023
+5,719
+69% +$15.9K ﹤0.01% 6586
2023
Q3 		$27.2K Sell
8,304
-1,143
-12% -$4.33K ﹤0.01% 6639
2023
Q2 		$42.3K Buy
9,447
+5,142
+119% +$25.1K ﹤0.01% 6569
2023
Q1 		$20.8K Sell
4,305
-2,984
-41% -$12.2K ﹤0.01% 7046
2022
Q4 		$22.8K Buy
7,289
+3,167
+77% +$9.9K ﹤0.01% 7515
2022
Q3 		$13K Sell
4,122
-2,289
-36% -$8.6K ﹤0.01% 8031
2022
Q2 		$23K Buy
6,411
+2,311
+56% +$7.97K ﹤0.01% 6699
2022
Q1 		$17K Sell
4,100
-6,397
-61% -$26.8K ﹤0.01% 7648
2021
Q4 		$57K Buy
10,497
+3,757
+56% +$25.9K ﹤0.01% 6778
2021
Q3 		$51K Buy
6,740
+2,640
+64% +$22.1K ﹤0.01% 6304
2021
Q2 		$41K Sell
4,100
-2,005
-33% -$22.6K ﹤0.01% 6610
2021
Q1 		$91K Buy
+6,105
New +$80.1K ﹤0.01% 6033

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group's GANX Position: Q2 2026 in Review

UBS Group reduced its Gain Therapeutics (GANX) stake by 2.5% in Q2 2026, selling an estimated $10.1K and leaving 215,012 shares worth $436K. The position accounts for ﹤0.01% of the portfolio, ranked #6330.

UBS Group first reported a position in GANX in Q1 2021 and has held it in 22 quarters since. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • UBS Group held 215,012 shares of Gain Therapeutics worth $436K as of Q2 2026.
  • UBS Group sold 5,477 Gain Therapeutics shares in Q2 2026, an estimated $10.1K.
  • Gain Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6330 holding.
  • UBS Group first reported a position in Gain Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.